These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 17164694)

  • 21. Differences in pharmacokinetic and electroencephalographic responses to caffeine in sleep-sensitive and non-sensitive subjects.
    Bchir F; Dogui M; Ben Fradj R; Arnaud MJ; Saguem S
    C R Biol; 2006 Jul; 329(7):512-9. PubMed ID: 16797457
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Propafenone-theophylline interaction.
    Spinler SA; Gammaitoni A; Charland SL; Hurwitz J
    Pharmacotherapy; 1993; 13(1):68-71. PubMed ID: 8437970
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessment of CYP1A2 activity in clinical practice: why, how, and when?
    Faber MS; Jetter A; Fuhr U
    Basic Clin Pharmacol Toxicol; 2005 Sep; 97(3):125-34. PubMed ID: 16128905
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers.
    Cai WM; Chen B; Zhou Y; Zhang YD
    Clin Pharmacol Ther; 1999 Nov; 66(5):516-21. PubMed ID: 10579479
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Interactions between digitoxin and some antiarrhythmic drugs.
    Sphakianaki E; Tsouderos I; Morali A; Kokkas B; Papadopoulos K; Kotoula M; Paradelis A
    Methods Find Exp Clin Pharmacol; 1992 Jun; 14(5):355-60. PubMed ID: 1513190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dose-dependent effect of propafenone on in vivo drug metabolism in the rat.
    Chong MT; Svensson CK
    Res Commun Chem Pathol Pharmacol; 1987 Nov; 58(2):147-56. PubMed ID: 3423421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Nonlinear pharmacokinetics of propafenone in rats and humans: application of a substrate depletion assay using hepatocytes for assessment of nonlinearity.
    Komura H; Iwaki M
    Drug Metab Dispos; 2005 Jun; 33(6):726-32. PubMed ID: 15743979
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin.
    Härtter S; Korhonen T; Lundgren S; Rane A; Tolonen A; Turpeinen M; Laine K
    Basic Clin Pharmacol Toxicol; 2006 Oct; 99(4):300-4. PubMed ID: 17040215
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the effect of ritlecitinib on the pharmacokinetics of caffeine in healthy participants.
    Liu J; Solan R; Wolk R; Plotka A; O'Gorman MT; Winton JA; Kaplan J; Purohit VS
    Br J Clin Pharmacol; 2023 Jul; 89(7):2208-2215. PubMed ID: 36808638
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Systemic clearance and demethylation of caffeine in sheep and cattle.
    Danielson TJ; Golsteyn LR
    Drug Metab Dispos; 1996 Oct; 24(10):1058-61. PubMed ID: 8894505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Effect of Qingkailing injection on rat CYP1A2 and CYP2D6 activity].
    Liu Y; Wang J; Bao YY; Yu WJ; Zhu DL
    Zhongguo Zhong Yao Za Zhi; 2007 Oct; 32(19):2044-7. PubMed ID: 18161301
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of coadministration of propafenone on the pharmacokinetics of digoxin in healthy volunteer subjects.
    Nolan PE; Marcus FI; Erstad BL; Hoyer GL; Furman C; Kirsten EB
    J Clin Pharmacol; 1989 Jan; 29(1):46-52. PubMed ID: 2708548
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro inhibition of CYP1A2 by model inhibitors, anti-inflammatory analgesics and female sex steroids: predictability of in vivo interactions.
    Karjalainen MJ; Neuvonen PJ; Backman JT
    Basic Clin Pharmacol Toxicol; 2008 Aug; 103(2):157-65. PubMed ID: 18816299
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artemisinin antimalarials moderately affect cytochrome P450 enzyme activity in healthy subjects.
    Asimus S; Elsherbiny D; Hai TN; Jansson B; Huong NV; Petzold MG; Simonsson US; Ashton M
    Fundam Clin Pharmacol; 2007 Jun; 21(3):307-16. PubMed ID: 17521300
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Two novel methods for the determination of CYP1A2 activity using the paraxanthine/caffeine ratio.
    Doude van Troostwijk LJ; Koopmans RP; Guchelaar HJ
    Fundam Clin Pharmacol; 2003 Jun; 17(3):355-62. PubMed ID: 12803575
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dose-dependent caffeine pharmacokinetics during severe sleep deprivation in humans.
    Kamimori GH; Lugo SI; Penetar DM; Chamberlain AC; Brunhart GE; Brunhart AE; Eddington ND
    Int J Clin Pharmacol Ther; 1995 Mar; 33(3):182-6. PubMed ID: 7599918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bioavailability of an extemporaneous suspension of propafenone made from tablets.
    Olguín HJ; Pérez CF; Pérez JF; Mendiola BR; Portugal MC; Chávez JB
    Biopharm Drug Dispos; 2006 Jul; 27(5):241-5. PubMed ID: 16586461
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Population pharmacokinetics of atazanavir in human immunodeficiency virus-infected patients.
    Solas C; Gagnieu MC; Ravaux I; Drogoul MP; Lafeuillade A; Mokhtari S; Lacarelle B; Simon N
    Ther Drug Monit; 2008 Dec; 30(6):670-3. PubMed ID: 18806695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rufinamide: clinical pharmacokinetics and concentration-response relationships in patients with epilepsy.
    Perucca E; Cloyd J; Critchley D; Fuseau E
    Epilepsia; 2008 Jul; 49(7):1123-41. PubMed ID: 18503564
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.